MediciNova received positive Optical Coherence Tomography (OCT) results from the company’s SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.
Urovant Sciences and Genmab reported disappointing clinical trial announcements.
Corbus Pharmaceuticals intends to restructure the company’s workforce and reallocate capital toward specific clinical and preclinical programs.
Swiss pharma giant Roche acquired Ireland’s Inflazome and the company’s NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases.
Vividion Therapeutics’ proteomics screening platform and small molecule library will be leveraged by the San Diego-based company and Roche to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.
The U.S. Food and Drug Administration approved Seattle Genetics’ Tukysa (tucatinib) in combination with chemotherapy agents trastuzumab and capecitabine for adults with HER2+ breast cancer that cannot be surgically removed or has metastasized to other parts of the body.
San Francisco-based Nurix closed an oversubscribed $120 million financing, with the round led by Foresite Capital.
Hundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
With a $75 million infusion of new financing, Massachusetts-based Arrakis Therapeutics will focus the company’s pipeline on oncology and genetically validated targets in other diseases.
Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.